home > ebr > winter 2019 > thinking throats with anatomical throat models
European Biopharmaceutical Review

Thinking Throats with Anatomical Throat Models

In recent years, anatomical throat models, for the purpose of generating aerodynamic particle size distribution (APSD) profiles for inhaled pharmaceutical products, have become increasingly utilised within the inhalation industry. This has been driven, at least in part, by the need to demonstrate the in vitro to in vivo relationship. The FDA has funded specific research in this area (1).

Historically, APSD data has been generated using the standard US Pharmacopeia (USP) throat (2). An appreciation of the differences between profiles generated using this and anatomically relevant throats is necessary to ensure that, when developing new inhalation products, consideration is given to showing in vitro equivalence. The use of an anatomical throat may also be a useful tool to facilitate in vivo therapeutic bioequivalence prediction.

This paper assesses the level of drug deposition in the throat, impactor sized mass (ISM), and <5μm fine particle mass (FPM<5μm) when assessing data generated using the Nanopharm anatomical throat and the Emmace medium throat model compared to the standard USP throat.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Alex Slowey is an inhalation formulation specialist at 3M Drug Delivery Systems. He earned his credentials as a pharmacist in 1997, and he joined the team at 3M later that year. Since then, he has held various roles within the R&D function at 3M DDSD. He is specialized in early phase development activities related to the formulation of new and established molecules for nasal and pulmonary delivery.

Samantha Holmes is an R&D Group Leader at 3M Drug Delivery Systems. She joined 3M in 2007 as an Analytical Chemist, after graduating from York University. She has worked with metred-dose inhalers for both early feasibility projects and late phase development programmes. Samantha specialises in analytical chemistry and works alongside the key R&D groups, supporting the development team.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health ( Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement